A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

Gynecologic Oncology

Volumn 116, Issue 3, 2010, Pages 332-334

  Rocereto, Thomas F ^a   Brady, William E ^b   Shahin, Mark S ^c   Hoffman, James S ^d   Small, Laurie ^e   Rotmensch, Jacob ^f   Mannel, Robert S ^g  

^a Department of Anesthesiology   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c ABINGTON MEMORIAL HOSPITAL   (United States)

^d NEW BRITAIN GENERAL HOSPITAL   (United States)

^e MAINE MEDICAL CENTER   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Epithelial ovarian cancer; Fallopian cancer; GOG; Mifepristone; Primary peritoneal cancer

Indexed keywords

MIFEPRISTONE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; UTERINE TUBE CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MIFEPRISTONE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 75749133558     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.071     Document Type: Article

References (9)

1. Ozols R.F., Rubin S.C., Thomas G., and Robboy S. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., et al. (Eds). Principles and practice of gynecologic oncology. 4th ed. (2005), Lippincott Williams & Wilkins 295-988
2. McGuire W.P., Hoskins W., Brady M., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
3. Armstrong D.K., Bundy B., and Wenzel. Intraperitoneal cisplatinum and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
4. Rao B.R., and Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 12 (1991) 14-26
5. Rose F.V., and Barnea E.R. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12 (1996) 999-1003
6. Rocereto T.F., Saul H.M., Aikins J.A., and Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol. Oncol. 77 (2000) 429-432
7. Therasse P., Arbuck S.G., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
8. Sill, M.W., Yothers, G. A method for utilizing bivariate efficacy outcome measures to screen agents for activity in the 2-stage phase II clinical trials, Technical Report 06-08, Department of Biostatistics, University of Buffalo. Website: http:/sphhp.buffalo.edu/biostat/research/techreports/index.php.
9. Clopper C.J., and Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26 (1934) 404-413